Fig. 8

Effects of Nano-DOX and DOX on the phenotype of MDSCs. a–d Proportion of MDSCs (Gr-1⁺/CD11b⁺) in bone marrow and expression of MDSCs markers (Gr-1 and CD11b) in bone marrow MDSCs from 4T1 tumor-bearing mice at the end of 3-week treatment of Nano-DOX or DOX. e–h Proportion of MDSCs (Gr-1⁺/CD11b⁺) in ex vivo bone marrow and expression of MDSCs markers (Gr-1 and CD11b) in ex vivo bone marrow. i–l Proportion of MDSCs (Gr-1⁺/CD11b⁺) in the blood and expression of MDSCs markers (Gr-1 and CD11b) in blood MDSCs from 4T1 tumor-bearing mice at the end of 3-week treatment of Nano-DOX or DOX. (Duration of Nano-DOX or DOX treatment was 72 h for all ex vivo cell experiments and cells were analyzed by immunofluorescent staining and FACS.) In FACS analysis, geometric means were used to quantify fluorescence intensity. Values were mean ± SD (n = 3 for ex vivo experiments and n = 4 for in vivo experiments, *p < 0.05, **p < 0.01)